•  I
• a · A  I
• Accesibility  I
• Map  I
• Search  I
• Staff directory

• ::  Iniciar sessió :: 

The Universitat Politècnica de València (UPV) and Ascires Biomedical Group have launched the new ASCIRES–UPV Joint Research Unit, with the aim of accelerating technological innovation applied to health and strengthening the transfer of knowledge between the university and clinical environments.

This new alliance between both entities will drive the development of biomarkers based on medical imaging and clinical data, the application of artificial intelligence in diagnosis and treatment, the evaluation of emerging healthcare techniques, their implementation in hospital settings, and the advanced characterization of clinical data across different specialties within this strategic partnership.

The creation of this new joint unit was formalized at an event held at the Ascires Hospital.

During the signing of the agreement, the Rector of UPV stated that for the institution, “it is a privilege to be able to work with a foundation and a hospital with the capabilities that Ascires has,” and he emphasized that this collaboration is taking place “at a moment of profound transformation in healthcare, in which technology, engineering, and digital medicine are driving a new revolution in health care.” According to him, this unit “will enable UPV to contribute decisively to the advancement of a rapidly evolving sector.”

The Rector also highlighted that UPV is currently “one of the leading technological universities in Europe in the field of biomedicine and biomedical engineering” and expressed confidence that the joint unit “will further strengthen collaboration with Ascires and the QUAES Foundation, generating a significant scientific, technological, and social impact.”

For her part, the CEO of Ascires, Lorena Saus, emphasized the innovative potential of this new unit: “For more than 10 years, we have collaborated with UPV through the university chair that we promote together with our QUAES Foundation, with excellent results. Now, with our Ascires Hospital, equipped with high medical technology, a new horizon opens up to strengthen collaboration with UPV in research and biomedical innovation, as well as in process reengineering, for more agile and higher-precision patient care.”

As Lorena Saus recalled, innovation is part of Ascires’ DNA, where maximizing AI and big data tools in biomedicine is already a reality: “We are very grateful to create this joint research unit with UPV, as it provides us with greater capacity for new developments for the benefit of our patients. In the field of diagnostic and treatment biomarkers, our focus will be on the areas of Cardiology, Oncology, Neurology, and the musculoskeletal system,” she specified.

After the signing, the UPV delegation visited different areas of the Ascires Hospital, such as Nuclear Medicine, Radiopharmacy, the Women’s Unit, the Neuroscience Area, Cardiology, Outpatient Clinics, Inpatient Care, and Radiotherapy, to gain a detailed understanding of the infrastructure that will host future joint scientific projects. The closing of the event included speeches by David Moratal, director of the Ascires/QUAES Foundation Chair at UPV; Nieves Romero, dean of the Official College of Industrial Engineers of the Valencian Community; and Lorena Saus Cano, CEO of Ascires Biomedical Group.